CN110167928A - 作为sos1抑制剂的新型经苄基氨基取代的喹唑啉和衍生物 - Google Patents

作为sos1抑制剂的新型经苄基氨基取代的喹唑啉和衍生物 Download PDF

Info

Publication number
CN110167928A
CN110167928A CN201780083358.7A CN201780083358A CN110167928A CN 110167928 A CN110167928 A CN 110167928A CN 201780083358 A CN201780083358 A CN 201780083358A CN 110167928 A CN110167928 A CN 110167928A
Authority
CN
China
Prior art keywords
alkyl
aryl
base
independently selected
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780083358.7A
Other languages
English (en)
Chinese (zh)
Inventor
M·格马其
M·山德森
D·凯斯勒
C·科芬克
M·R·内瑟顿
J·莱姆哈特
T·温伯格
M·霍夫曼
F·萨瓦雷斯
A·鲍姆
D·鲁道夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN110167928A publication Critical patent/CN110167928A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CN201780083358.7A 2016-12-22 2017-12-21 作为sos1抑制剂的新型经苄基氨基取代的喹唑啉和衍生物 Pending CN110167928A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16206422 2016-12-22
EP16206422.4 2016-12-22
PCT/EP2017/084265 WO2018115380A1 (en) 2016-12-22 2017-12-21 Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors

Publications (1)

Publication Number Publication Date
CN110167928A true CN110167928A (zh) 2019-08-23

Family

ID=57777432

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780083358.7A Pending CN110167928A (zh) 2016-12-22 2017-12-21 作为sos1抑制剂的新型经苄基氨基取代的喹唑啉和衍生物

Country Status (5)

Country Link
US (2) US10898487B2 (cg-RX-API-DMAC7.html)
EP (2) EP3558979B1 (cg-RX-API-DMAC7.html)
JP (1) JP7219218B2 (cg-RX-API-DMAC7.html)
CN (1) CN110167928A (cg-RX-API-DMAC7.html)
WO (1) WO2018115380A1 (cg-RX-API-DMAC7.html)

Cited By (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112174891A (zh) * 2020-11-02 2021-01-05 浙江省农业科学院 一种氟唑菌苯胺代谢物的制备方法
WO2021203768A1 (zh) * 2020-04-08 2021-10-14 江苏恒瑞医药股份有限公司 嘧啶并二环类衍生物、其制备方法及其在医药上的应用
WO2021228028A1 (zh) * 2020-05-09 2021-11-18 正大天晴药业集团股份有限公司 含磷的sos1抑制剂
CN113767100A (zh) * 2019-03-01 2021-12-07 锐新医药公司 双环杂芳基化合物及其用途
WO2021249519A1 (zh) * 2020-06-11 2021-12-16 江苏恒瑞医药股份有限公司 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用
CN113801114A (zh) * 2020-06-11 2021-12-17 江苏恒瑞医药股份有限公司 稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用
CN113912608A (zh) * 2020-07-10 2022-01-11 江苏恒瑞医药股份有限公司 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用
WO2022017519A1 (zh) * 2020-07-24 2022-01-27 南京明德新药研发有限公司 喹唑啉类化合物
WO2022017339A1 (zh) * 2020-07-20 2022-01-27 江苏恒瑞医药股份有限公司 稠合哒嗪类衍生物、其制备方法及其在医药上的应用
WO2022028506A1 (zh) * 2020-08-06 2022-02-10 北京泰德制药股份有限公司 Sos1抑制剂、包含其的药物组合物及其用途
WO2022083657A1 (zh) * 2020-10-20 2022-04-28 苏州泽璟生物制药股份有限公司 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
CN114436976A (zh) * 2021-01-29 2022-05-06 石药集团中奇制药技术(石家庄)有限公司 一种新型喹唑啉类衍生物及其制备和应用
CN114524810A (zh) * 2020-11-21 2022-05-24 上海凌达生物医药有限公司 一类嘧啶并杂环类化合物、制备方法和用途
CN114621231A (zh) * 2020-12-14 2022-06-14 杭州中美华东制药有限公司 一种靶向降解/抑制活性的嵌合化合物及其制备方法和用途
WO2022121813A1 (zh) * 2020-12-07 2022-06-16 北京泰德制药股份有限公司 Sos1抑制剂、包含其的药物组合物及其用途
WO2022135610A1 (zh) * 2020-12-25 2022-06-30 武汉誉祥医药科技有限公司 四并环化合物及其药物组合物和应用
CN114685488A (zh) * 2020-12-31 2022-07-01 南京圣和药业股份有限公司 作为sos1抑制剂的化合物及其应用
CN114685487A (zh) * 2020-12-27 2022-07-01 上海凌达生物医药有限公司 一类嘧啶并杂环类化合物、制备方法和用途
WO2022143533A1 (zh) * 2020-12-30 2022-07-07 成都百裕制药股份有限公司 喹唑啉衍生物及其在医药上的应用
CN114716477A (zh) * 2021-01-07 2022-07-08 武汉人福创新药物研发中心有限公司 7-取代磷酰基喹唑啉类衍生物及其制备方法和用途
CN114746411A (zh) * 2019-11-29 2022-07-12 印度鲁宾有限公司 取代的三环化合物
WO2022148442A1 (zh) * 2021-01-07 2022-07-14 武汉人福创新药物研发中心有限公司 6-取代磷酰基喹唑啉类衍生物及其制备方法和用途
CN114835703A (zh) * 2021-02-02 2022-08-02 苏州泽璟生物制药股份有限公司 取代嘧啶并吡啶酮类抑制剂及其制备方法和应用
WO2022161461A1 (zh) * 2021-01-29 2022-08-04 江苏先声药业有限公司 Sos1抑制剂及其制备方法和应用
CN114853812A (zh) * 2021-02-04 2022-08-05 四川科伦博泰生物医药股份有限公司 含氧化膦基团的化合物、其制备方法及其在医药上的应用
WO2022166974A1 (zh) * 2021-02-08 2022-08-11 武汉人福创新药物研发中心有限公司 吡啶并嘧啶酮类衍生物及其制备方法和用途
CN114901662A (zh) * 2019-11-08 2022-08-12 锐新医药公司 双环杂芳基化合物及其用途
CN114907324A (zh) * 2021-02-09 2022-08-16 苏州泽璟生物制药股份有限公司 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
CN114907284A (zh) * 2021-02-10 2022-08-16 石药集团中奇制药技术(石家庄)有限公司 一种具有抗肿瘤活性的化合物及其用途
WO2022170802A1 (zh) * 2021-02-09 2022-08-18 苏州阿尔脉生物科技有限公司 一种作为sos1抑制剂的嘧啶并吡啶酮类衍生物、其制备方法及用途
WO2022171018A1 (zh) * 2021-02-09 2022-08-18 苏州泽璟生物制药股份有限公司 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
WO2022171184A1 (zh) * 2021-02-10 2022-08-18 杭州英创医药科技有限公司 作为sos1抑制剂的杂环化合物
WO2022170917A1 (zh) * 2021-02-09 2022-08-18 苏州阿尔脉生物科技有限公司 一种作为sos1抑制剂的多环嘧啶类衍生物、其制备方法及用途
CN115028644A (zh) * 2021-03-08 2022-09-09 首药控股(北京)股份有限公司 Sos1抑制剂杂环化合物
WO2022184116A1 (zh) * 2021-03-05 2022-09-09 江苏先声药业有限公司 新型sos1抑制剂及其制备方法和应用
CN115043817A (zh) * 2021-03-09 2022-09-13 苏州泽璟生物制药股份有限公司 Sos1蛋白水解调节剂及其制备方法和应用
WO2022199635A1 (zh) * 2021-03-25 2022-09-29 南京明德新药研发有限公司 苄氨基喹唑啉类衍生物
WO2022199670A1 (zh) * 2021-03-26 2022-09-29 南京明德新药研发有限公司 6-氨基甲酸酯取代的杂芳环衍生物
CN115197218A (zh) * 2021-04-14 2022-10-18 苏州信诺维医药科技股份有限公司 一种稠环化合物及其应用
CN115215884A (zh) * 2021-04-19 2022-10-21 昆药集团股份有限公司 苯并嘧啶三环类衍生物及其制备方法和应用
CN115215847A (zh) * 2021-04-16 2022-10-21 中国科学院上海药物研究所 一类kras-sos1抑制剂、其制备方法及其应用
CN115232108A (zh) * 2021-04-23 2022-10-25 上海领泰生物医药科技有限公司 Sos1降解剂及其制备方法和应用
WO2022222875A1 (zh) * 2021-04-19 2022-10-27 昆药集团股份有限公司 一种苯并嘧啶三环衍生物及其制备方法和应用
CN115246841A (zh) * 2021-09-14 2022-10-28 北京福元医药股份有限公司 苄氨基取代的嘧啶并吡喃酮衍生物及其组合物、制剂和用途
CN115417868A (zh) * 2021-09-13 2022-12-02 石药集团中奇制药技术(石家庄)有限公司 一种具有抗肿瘤活性的杂环化合物及其用途
WO2022258057A1 (en) * 2021-06-11 2022-12-15 Jingrui Biopharma Co., Ltd. Compounds as anticancer agents
WO2022262691A1 (en) * 2021-06-17 2022-12-22 Beijing Innocare Pharma Tech Co., Ltd. Heterocyclic compounds as sos1 inhibitors
WO2022268209A1 (zh) * 2021-06-24 2022-12-29 四川汇宇制药股份有限公司 一种嘧啶并环结构衍生物及其用途
CN115536660A (zh) * 2021-11-04 2022-12-30 北京福元医药股份有限公司 苄氨基取代的杂多环化合物及其组合物、制剂和用途
CN115605476A (zh) * 2019-12-27 2023-01-13 鲁宾有限公司(In) 取代的三环化合物
WO2023001229A1 (zh) * 2021-07-23 2023-01-26 浙江海正药业股份有限公司 嘧啶并环类衍生物及其制备方法和用途
CN115677601A (zh) * 2021-07-29 2023-02-03 石药集团中奇制药技术(石家庄)有限公司 一种具有抗肿瘤活性的化合物及其用途
CN115697994A (zh) * 2020-06-10 2023-02-03 江苏恒瑞医药股份有限公司 稠合喹唑啉类衍生物、其制备方法及其在医药上的应用
CN115677699A (zh) * 2021-07-23 2023-02-03 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
CN115677824A (zh) * 2021-07-26 2023-02-03 中国科学院上海药物研究所 可诱导sos1蛋白质降解的化合物、制备方法和用途
WO2023030216A1 (zh) * 2021-08-30 2023-03-09 浙江海正药业股份有限公司 喹唑啉类衍生物、或其制备方法和用途
CN115942936A (zh) * 2020-06-24 2023-04-07 勃林格殷格翰国际有限公司 包含sos1抑制剂和kras g12c抑制剂的抗癌组合疗法
CN116143708A (zh) * 2021-11-21 2023-05-23 四川汇宇制药股份有限公司 一种多取代苯并氮杂芳基衍生物及其用途
WO2023109929A1 (zh) 2021-12-17 2023-06-22 石药集团中奇制药技术(石家庄)有限公司 一种具有抗肿瘤活性的杂环化合物及其用途
CN116444447A (zh) * 2023-06-19 2023-07-18 中国药科大学 一种sos1和hdac双靶点喹唑啉羟肟酸化合物及其制法和应用
WO2023138526A1 (zh) * 2022-01-21 2023-07-27 南京明德新药研发有限公司 含烯丙基的甲基吡啶并嘧啶化合物的晶型
WO2023143147A1 (zh) * 2022-01-28 2023-08-03 上海优理惠生医药有限公司 一种哒嗪并吡啶酮类化合物、其药物组合物及应用
CN116546985A (zh) * 2021-01-28 2023-08-04 浙江海正药业股份有限公司 吡啶并嘧啶类衍生物及其制备方法和用途
CN116648250A (zh) * 2020-12-22 2023-08-25 韩美药品株式会社 作为sos1抑制剂的新型喹唑啉衍生物及其用途
CN116768858A (zh) * 2022-03-15 2023-09-19 杭州中美华东制药有限公司 具有kras-sos1抑制或降解活性的嵌合化合物及其用途
CN117024404A (zh) * 2022-05-10 2023-11-10 四川汇宇制药股份有限公司 苯并吡啶衍生物及其用途
WO2023241414A1 (zh) * 2022-06-13 2023-12-21 上海优理惠生医药有限公司 一种哒嗪类化合物、其药物组合物及应用
WO2024008185A1 (zh) * 2022-07-07 2024-01-11 武汉人福创新药物研发中心有限公司 包含sos1抑制剂的药物组合物
CN117651701A (zh) * 2021-03-02 2024-03-05 唯久生物技术(苏州)有限公司 作为sos1抑制剂的新型取代的二环氮杂杂环
WO2024061353A1 (zh) * 2022-09-23 2024-03-28 南京明德新药研发有限公司 喹唑啉类化合物的晶型及其制备方法
CN119907792A (zh) * 2022-10-21 2025-04-29 领泰生物医药(绍兴)有限公司 苄基或噻吩亚甲基取代的氨基喹唑啉衍生物及其作为sos1降解剂的用途

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2863873T3 (es) 2016-05-18 2021-10-11 Mirati Therapeutics Inc Inhibidores de KRAS G12C
EP3558979B1 (en) 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
WO2018126192A1 (en) * 2016-12-30 2018-07-05 Children's Medical Center Corporation Map2k1 (mek1) as a therapeutic target for arteriovenous malformations and associated disorders
CA3056970A1 (en) * 2017-03-21 2018-09-27 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
CA3082579A1 (en) 2017-11-15 2019-05-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
PL3728254T3 (pl) 2017-12-21 2023-06-12 Boehringer Ingelheim International Gmbh Benzyloaminopodstawione pirydopirymidynony i pochodne jako inhibitory sos1
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EP3781565A1 (en) * 2018-04-18 2021-02-24 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
AU2019338207B2 (en) 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
US12377101B2 (en) 2018-12-05 2025-08-05 Mirati Therapeutics, Inc. Combination therapies
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
US20230096028A1 (en) * 2019-03-01 2023-03-30 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
MA56022A (fr) 2019-05-31 2022-04-06 Chiesi Farm Spa Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3
US20220249492A1 (en) * 2019-06-19 2022-08-11 Boehringer Ingelheim International Gmbh Anticancer combination therapy
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療braf相關的疾病和失調症之化合物
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
GEP20247638B (en) * 2019-10-22 2024-07-10 Lupin Ltd Pharmaceutical combination of prmt5 inhibitors
US20230145356A1 (en) 2019-11-18 2023-05-11 Inxmed (Nanjing) Co., Ltd. Use of fak inhibitor in preparation of drug for treating tumors having nras mutation
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
CA3170923A1 (en) 2020-04-28 2021-11-04 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors i
EP3903582A1 (en) 2020-04-28 2021-11-03 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors ii
EP3903583A1 (en) 2020-04-28 2021-11-03 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors iii
IL297584B1 (en) 2020-04-28 2026-07-01 Basf Se Use of strobilurin compounds to control phytopathogenic fungi containing an F129L amino acid substitution in mitochondrial cytochrome B protein that confers resistance to QO III inhibitors
BR112022021734A2 (pt) 2020-04-28 2022-12-06 Basf Se Uso de compostos de fórmula i, métodos para combater fungos fitopatogênicos, compostos e composições agroquímicas
EP3903581A1 (en) 2020-04-28 2021-11-03 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors i
EP3903584A1 (en) 2020-04-28 2021-11-03 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors iv
IL297583B1 (en) 2020-04-28 2026-07-01 Basf Se Use of strobilurin compounds to control phytopathogenic fungi containing an F129L amino acid substitution in mitochondrial cytochrome B protein that confers resistance to QO II inhibitors
CN116034106B (zh) 2020-06-02 2025-11-04 勃林格殷格翰国际有限公司 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物
MX2022015703A (es) 2020-06-09 2023-01-24 Array Biopharma Inc Compuestos para el tratamiento de enfermedades y trastornos asociados a braf.
US12655160B2 (en) 2020-08-04 2026-06-16 Mirati Therapeutics, Inc. KRAS G12D inhibitors
EP3970494A1 (en) 2020-09-21 2022-03-23 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors viii
WO2022033906A1 (en) 2020-08-11 2022-02-17 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors viii
CA3191279A1 (en) 2020-08-28 2022-03-03 Yi Liu Heterocyclic compounds and uses thereof
EP4208261A1 (en) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
US20240025863A1 (en) * 2020-09-16 2024-01-25 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
US20230357239A1 (en) * 2020-09-18 2023-11-09 Bayer Aktiengesellschaft Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors
EP4216951B1 (en) 2020-09-22 2026-04-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2022109171A1 (en) * 2020-11-18 2022-05-27 Modernatx, Inc. Ribonucleic acid purification
EP4262807A4 (en) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
WO2022133038A1 (en) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
AU2021409816A1 (en) 2020-12-22 2023-07-06 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
KR20230137368A (ko) 2021-01-19 2023-10-04 루핀 리미티드 암을 치료 및/또는 예방하기 위한 sos1 저해제들의약학적 조합물
WO2022156792A1 (en) * 2021-01-25 2022-07-28 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as sos1 inhibitors
CN114835719A (zh) * 2021-02-01 2022-08-02 苏州泽璟生物制药股份有限公司 取代双环并芳杂环胺类抑制剂及其制备方法和应用
WO2022187411A1 (en) 2021-03-02 2022-09-09 Kumquat Biosciences Inc. Heterocycles and uses thereof
US20240197888A1 (en) * 2021-03-17 2024-06-20 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
GB202104609D0 (en) 2021-03-31 2021-05-12 Sevenless Therapeutics Ltd New Treatments for Pain
WO2022212531A1 (en) * 2021-03-31 2022-10-06 Acerand Therapeutics (Usa) Limited Pyridopyrimidinone compounds
EP4313151A1 (en) 2021-03-31 2024-02-07 Sevenless Therapeutics Limited Sos1 inhibitors and ras inhibitors for use in the treatment of pain
JP2024514127A (ja) 2021-04-09 2024-03-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗がん剤療法
CN117979966A (zh) * 2021-04-09 2024-05-03 锐新医药公司 使用sos1抑制剂和ras抑制剂治疗癌症
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
JP2024521788A (ja) * 2021-05-27 2024-06-04 ミラティ セラピューティクス, インコーポレイテッド 併用療法
JP2024522768A (ja) * 2021-06-16 2024-06-21 バイオセリックス, インコーポレイテッド Sos1タンパク質分解剤、その医薬組成物及びそれらの治療的応用
US20250059182A1 (en) 2021-06-21 2025-02-20 Mirati Therapeutics, Inc. Sos1 inhibitors
CA3227026A1 (en) * 2021-08-03 2023-02-09 Evopoint Biosciences Co., Ltd. Fused ring compound, pharmaceutical composition, and application thereof
CN117957226A (zh) 2021-09-17 2024-04-30 南京再明医药有限公司 作为sos1抑制剂的杂环化合物及其用途
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
US20240425501A1 (en) * 2021-10-21 2024-12-26 Sanjita Sasmal Novel bicyclic heteroaryl derivatives as sos1:kras proteinprotein interaction inhibitors
WO2023072670A1 (en) 2021-10-28 2023-05-04 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors x
WO2023072671A1 (en) 2021-10-28 2023-05-04 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors ix
TW202340208A (zh) 2021-12-01 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
TW202337432A (zh) 2021-12-01 2023-10-01 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
CR20240233A (es) 2021-12-01 2024-07-17 Univ Vanderbilt Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cáncer
EP4441050A1 (en) 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
EP4441051A1 (en) 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
WO2023098825A1 (zh) * 2021-12-02 2023-06-08 勤浩医药(苏州)有限公司 Sos1抑制剂、包含其的药物组合物及其用途
KR20240115893A (ko) 2021-12-08 2024-07-26 어레이 바이오파마 인크. N-(2-클로로-3-((5-클로로-3-메틸-4-옥소-3,4-다이하이드로퀴나졸린-6-일)아미노)-4-플루오로페닐)-3-플루오로아제티딘-1-설폰아미드의결정질 형태
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
EP4463454A1 (en) 2022-01-14 2024-11-20 Jazz Pharmaceuticals Ireland Limited Novel amine-substituted phthalazines and derivatives as sos1 inhibitors
KR20230121208A (ko) 2022-02-10 2023-08-18 (주)파로스아이바이오 Sos1 억제제 및 이의 유도체
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
US12419962B2 (en) 2022-03-16 2025-09-23 Biotheryx, Inc. Quinazolines, pharmaceutical compositions, and therapeutic applications
GB202203976D0 (en) 2022-03-22 2022-05-04 Jazz Pharmaceuticals Ireland Ltd Tricyclic phthalazines and derivatives as sos1 inhibitors
CA3244999A1 (en) 2022-03-31 2025-06-13 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumors
KR20240170920A (ko) * 2022-04-08 2024-12-05 미라티 테라퓨틱스, 인크. Sos1 억제제 및 egfr 억제제를 포함하는 병용 요법
CN118973580A (zh) * 2022-04-08 2024-11-15 米拉蒂治疗股份有限公司 包含sos1抑制剂和mek抑制剂的组合疗法
EP4511128A1 (en) * 2022-04-20 2025-02-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
EP4536364A1 (en) 2022-06-10 2025-04-16 Revolution Medicines, Inc. Macrocyclic ras inhibitors
JP2025528836A (ja) 2022-08-17 2025-09-02 ツリーライン バイオサイエンシズ インコーポレイテッド ピリドピリミジンKRas阻害剤
WO2024056782A1 (en) 2022-09-16 2024-03-21 Bayer Aktiengesellschaft Sulfone-substituted pyrido[3,4-d]pyrimidine derivatives for the treatment of cancer
EP4598538A1 (en) 2022-10-05 2025-08-13 Sevenless Therapeutics Limited New treatments for pain
IL319779A (en) * 2022-10-07 2025-05-01 Jeil Pharmaceutical Co Ltd New bicyclic heterocyclic compounds and their uses
CN120112538A (zh) 2022-10-13 2025-06-06 拜耳公司 Sos1抑制剂
US20240208909A1 (en) * 2022-12-02 2024-06-27 Accutar Biotechnology Inc. Substituted quinoline derivatives having sos1 inhibition activities and uses thereof
WO2024160734A1 (de) 2023-02-01 2024-08-08 Deutsche Institute Für Textil- Und Faserforschung Denkendorf Amin-funktionalisiertes cellulosematerial, verfahren zu dessen herstellung und verwendung als co2-adsorber
KR20250166103A (ko) 2023-04-06 2025-11-27 에자이 알앤드디 매니지먼트 가부시키가이샤 종양 치료용 약제학적 조성물
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
CN121487951A (zh) 2023-04-07 2026-02-06 锐新医药公司 大环ras抑制剂
AU2024251341A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
EP4695261A1 (en) 2023-04-14 2026-02-18 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
WO2024243441A1 (en) 2023-05-24 2024-11-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
US20250019385A1 (en) 2023-05-30 2025-01-16 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
EP4722213A1 (en) 2023-05-31 2026-04-08 Sichuan Huiyu Pharmaceutical Co., Ltd. Nitrogen-containing functional group-substituted pyridazinopyridone derivative and use thereof
GB2631397A (en) 2023-06-28 2025-01-08 Sevenless Therapeutics Ltd New treatments for pain
EP4735451A1 (en) 2023-06-30 2026-05-06 Kumquat Biosciences Inc. Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
WO2025006967A1 (en) 2023-06-30 2025-01-02 Bristol-Myers Squibb Company Kras inhibitors
TW202515575A (zh) 2023-09-11 2025-04-16 美商金橘生物科技公司 細胞增殖調節劑及其用途
WO2025064848A1 (en) 2023-09-21 2025-03-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyridine kras inhibitors
GB2633813A (en) 2023-09-21 2025-03-26 Sevenless Therapeutics Ltd New treatments for pain
WO2025083426A1 (en) 2023-10-20 2025-04-24 Sevenless Therapeutics Limited New treatments for pain
WO2025090812A1 (en) * 2023-10-25 2025-05-01 Kumquat Biosciences Inc. Methods of modulating cell proliferation
WO2025090810A1 (en) 2023-10-25 2025-05-01 Kumquat Biosciences Inc. Use of sos1 inhibitors and amivantamab to treat cancer
WO2025090808A1 (en) 2023-10-25 2025-05-01 Kumquat Biosciences Inc. Combinations of sos-1 inhibitors with osimertinib and/or met inhibitors to treat cancer
AU2024404879A1 (en) 2023-12-22 2026-06-25 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025146548A1 (en) 2024-01-04 2025-07-10 Sevenless Therapeutics Limited Sos1 inhibitors useful to treat pain and cancer
WO2025171055A1 (en) 2024-02-06 2025-08-14 Kumquat Biosciences Inc. Heterocyclic conjugates and uses thereof
WO2025202022A1 (en) 2024-03-27 2025-10-02 Bayer Aktiengesellschaft Anticancer macrocyclic quinazoline-based inhibitors of the ineraction between ras and sos1
TW202606709A (zh) 2024-04-03 2026-02-16 德商百靈佳殷格翰國際股份有限公司 抗癌組合療法
WO2025230971A1 (en) 2024-04-30 2025-11-06 Kumquat Biosciences Inc. Macrocyclic heterocycles as anticancer agents
WO2025245127A1 (en) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
WO2026114918A1 (en) 2024-11-27 2026-06-04 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophene derivatives as kras inhibitors for the treatment of cancer
US20260146049A1 (en) 2024-11-27 2026-05-28 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
US20260146050A1 (en) 2024-11-27 2026-05-28 Boehringer Ingelheim International Gmbh Kras degrading compounds comprising spirocyclic annulated 2 amino-3-cyano thiophenes
WO2026114957A1 (en) 2024-11-27 2026-06-04 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophene derivatives as kras degraders for the treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150118A2 (en) * 2007-06-05 2008-12-11 Hanmi Pharm. Co., Ltd. Novel amide derivative for inhibiting the growth of cancer cells
WO2016077793A1 (en) * 2014-11-14 2016-05-19 Children's Hospital Medical Center Sos1 inhibitors for cancer treatment

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US6174899B1 (en) 1998-05-14 2001-01-16 Morton Shulman Orally administered analgesic composition comprising myfadol
WO2004003152A2 (en) * 2002-06-26 2004-01-08 Chiron Corporation Sos1 inhibitors
EP2139895A1 (en) 2007-03-23 2010-01-06 F. Hoffmann-Roche AG Aza-pyridopyrimidinone derivatives
EP2330909B1 (en) 2008-08-12 2013-09-18 GlaxoSmithKline LLC Chemical compounds
US20110230499A1 (en) 2008-11-28 2011-09-22 Novartis Ag Hsp90 inhibitors for therapeutic treatment
UY32317A (es) 2008-12-12 2010-07-30 Boehringer Ingelheim Int Anticuerpos anti-igf
JP5993742B2 (ja) 2009-10-29 2016-09-14 ジェノスコ キナーゼ阻害剤
CN103562145B (zh) 2010-12-06 2016-09-21 颇尔公司 生物制品的连续加工方法
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
MA37405A1 (fr) 2012-03-14 2016-03-31 Lupin Ltd Composés hétérocyclyle
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
TW201524952A (zh) 2013-03-15 2015-07-01 Araxes Pharma Llc Kras g12c之共價抑制劑
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
EP3558979B1 (en) * 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
CA3056970A1 (en) 2017-03-21 2018-09-27 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
US20220249492A1 (en) 2019-06-19 2022-08-11 Boehringer Ingelheim International Gmbh Anticancer combination therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150118A2 (en) * 2007-06-05 2008-12-11 Hanmi Pharm. Co., Ltd. Novel amide derivative for inhibiting the growth of cancer cells
WO2016077793A1 (en) * 2014-11-14 2016-05-19 Children's Hospital Medical Center Sos1 inhibitors for cancer treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JU HOU: "Design, synthesis, anti-tumor activity, and molecular modeling of", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 *

Cited By (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113767100A (zh) * 2019-03-01 2021-12-07 锐新医药公司 双环杂芳基化合物及其用途
CN116425742A (zh) * 2019-11-08 2023-07-14 锐新医药公司 双环杂芳基化合物及其用途
CN114901662A (zh) * 2019-11-08 2022-08-12 锐新医药公司 双环杂芳基化合物及其用途
CN114746411A (zh) * 2019-11-29 2022-07-12 印度鲁宾有限公司 取代的三环化合物
CN114746411B (zh) * 2019-11-29 2024-06-25 印度鲁宾有限公司 取代的三环化合物
CN115605476A (zh) * 2019-12-27 2023-01-13 鲁宾有限公司(In) 取代的三环化合物
WO2021203768A1 (zh) * 2020-04-08 2021-10-14 江苏恒瑞医药股份有限公司 嘧啶并二环类衍生物、其制备方法及其在医药上的应用
CN115244058A (zh) * 2020-04-08 2022-10-25 江苏恒瑞医药股份有限公司 嘧啶并二环类衍生物、其制备方法及其在医药上的应用
CN115461342A (zh) * 2020-05-09 2022-12-09 正大天晴药业集团股份有限公司 含磷的sos1抑制剂
WO2021228028A1 (zh) * 2020-05-09 2021-11-18 正大天晴药业集团股份有限公司 含磷的sos1抑制剂
US12565511B2 (en) 2020-05-09 2026-03-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. SOS1 inhibitor containing phosphorus
CN115697994A (zh) * 2020-06-10 2023-02-03 江苏恒瑞医药股份有限公司 稠合喹唑啉类衍生物、其制备方法及其在医药上的应用
CN115605479B (zh) * 2020-06-11 2024-05-14 江苏恒瑞医药股份有限公司 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用
CN113801114B (zh) * 2020-06-11 2022-11-18 江苏恒瑞医药股份有限公司 稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用
CN113801114A (zh) * 2020-06-11 2021-12-17 江苏恒瑞医药股份有限公司 稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用
CN115605479A (zh) * 2020-06-11 2023-01-13 江苏恒瑞医药股份有限公司(Cn) 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用
WO2021249519A1 (zh) * 2020-06-11 2021-12-16 江苏恒瑞医药股份有限公司 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用
CN115942936A (zh) * 2020-06-24 2023-04-07 勃林格殷格翰国际有限公司 包含sos1抑制剂和kras g12c抑制剂的抗癌组合疗法
CN113912608A (zh) * 2020-07-10 2022-01-11 江苏恒瑞医药股份有限公司 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用
WO2022017339A1 (zh) * 2020-07-20 2022-01-27 江苏恒瑞医药股份有限公司 稠合哒嗪类衍生物、其制备方法及其在医药上的应用
CN116234807B (zh) * 2020-07-24 2025-10-14 南京明德新药研发有限公司 喹唑啉类化合物
US12552787B2 (en) 2020-07-24 2026-02-17 Medshine Discovery Inc. Quinazoline compound
WO2022017519A1 (zh) * 2020-07-24 2022-01-27 南京明德新药研发有限公司 喹唑啉类化合物
CN116234807A (zh) * 2020-07-24 2023-06-06 南京明德新药研发有限公司 喹唑啉类化合物
WO2022028506A1 (zh) * 2020-08-06 2022-02-10 北京泰德制药股份有限公司 Sos1抑制剂、包含其的药物组合物及其用途
CN116194446A (zh) * 2020-08-06 2023-05-30 北京泰德制药股份有限公司 Sos1抑制剂、包含其的药物组合物及其用途
WO2022083657A1 (zh) * 2020-10-20 2022-04-28 苏州泽璟生物制药股份有限公司 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
CN112174891B (zh) * 2020-11-02 2022-02-01 浙江省农业科学院 一种氟唑菌苯胺代谢物的制备方法
CN112174891A (zh) * 2020-11-02 2021-01-05 浙江省农业科学院 一种氟唑菌苯胺代谢物的制备方法
CN114524810A (zh) * 2020-11-21 2022-05-24 上海凌达生物医药有限公司 一类嘧啶并杂环类化合物、制备方法和用途
CN114524810B (zh) * 2020-11-21 2023-12-01 上海凌达生物医药有限公司 一类嘧啶并杂环类化合物、制备方法和用途
WO2022105921A1 (zh) * 2020-11-21 2022-05-27 上海凌达生物医药有限公司 一类嘧啶并杂环类化合物、制备方法和用途
CN116568681A (zh) * 2020-12-07 2023-08-08 北京泰德制药股份有限公司 Sos1抑制剂、包含其的药物组合物及其用途
WO2022121813A1 (zh) * 2020-12-07 2022-06-16 北京泰德制药股份有限公司 Sos1抑制剂、包含其的药物组合物及其用途
CN114621231A (zh) * 2020-12-14 2022-06-14 杭州中美华东制药有限公司 一种靶向降解/抑制活性的嵌合化合物及其制备方法和用途
CN116648250A (zh) * 2020-12-22 2023-08-25 韩美药品株式会社 作为sos1抑制剂的新型喹唑啉衍生物及其用途
WO2022135610A1 (zh) * 2020-12-25 2022-06-30 武汉誉祥医药科技有限公司 四并环化合物及其药物组合物和应用
CN114685531A (zh) * 2020-12-25 2022-07-01 武汉誉祥医药科技有限公司 四并环化合物及其药物组合物和应用
CN114685487B (zh) * 2020-12-27 2024-04-19 上海凌达生物医药有限公司 一类嘧啶并杂环类化合物、制备方法和用途
CN114685487A (zh) * 2020-12-27 2022-07-01 上海凌达生物医药有限公司 一类嘧啶并杂环类化合物、制备方法和用途
CN116249529B (zh) * 2020-12-30 2025-06-06 康百达(四川)生物医药科技有限公司 喹唑啉衍生物及其在医药上的应用
WO2022143533A1 (zh) * 2020-12-30 2022-07-07 成都百裕制药股份有限公司 喹唑啉衍生物及其在医药上的应用
CN116249529A (zh) * 2020-12-30 2023-06-09 成都百裕制药股份有限公司 喹唑啉衍生物及其在医药上的应用
CN114685488A (zh) * 2020-12-31 2022-07-01 南京圣和药业股份有限公司 作为sos1抑制剂的化合物及其应用
CN114716477A (zh) * 2021-01-07 2022-07-08 武汉人福创新药物研发中心有限公司 7-取代磷酰基喹唑啉类衍生物及其制备方法和用途
WO2022148442A1 (zh) * 2021-01-07 2022-07-14 武汉人福创新药物研发中心有限公司 6-取代磷酰基喹唑啉类衍生物及其制备方法和用途
CN116546985A (zh) * 2021-01-28 2023-08-04 浙江海正药业股份有限公司 吡啶并嘧啶类衍生物及其制备方法和用途
CN117279914A (zh) * 2021-01-29 2023-12-22 南京再明医药有限公司 Sos1抑制剂及其制备方法和应用
CN114436976A (zh) * 2021-01-29 2022-05-06 石药集团中奇制药技术(石家庄)有限公司 一种新型喹唑啉类衍生物及其制备和应用
WO2022161461A1 (zh) * 2021-01-29 2022-08-04 江苏先声药业有限公司 Sos1抑制剂及其制备方法和应用
WO2022166592A1 (zh) * 2021-02-02 2022-08-11 苏州泽璟生物制药股份有限公司 取代嘧啶并吡啶酮类抑制剂及其制备方法和应用
CN114835703A (zh) * 2021-02-02 2022-08-02 苏州泽璟生物制药股份有限公司 取代嘧啶并吡啶酮类抑制剂及其制备方法和应用
CN114853812A (zh) * 2021-02-04 2022-08-05 四川科伦博泰生物医药股份有限公司 含氧化膦基团的化合物、其制备方法及其在医药上的应用
WO2022166974A1 (zh) * 2021-02-08 2022-08-11 武汉人福创新药物研发中心有限公司 吡啶并嘧啶酮类衍生物及其制备方法和用途
CN116568689B (zh) * 2021-02-09 2025-07-11 苏州阿尔脉生物科技有限公司 一种作为sos1抑制剂的多环嘧啶类衍生物、其制备方法及用途
CN114907324A (zh) * 2021-02-09 2022-08-16 苏州泽璟生物制药股份有限公司 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
WO2022170917A1 (zh) * 2021-02-09 2022-08-18 苏州阿尔脉生物科技有限公司 一种作为sos1抑制剂的多环嘧啶类衍生物、其制备方法及用途
CN116568689A (zh) * 2021-02-09 2023-08-08 苏州阿尔脉生物科技有限公司 一种作为sos1抑制剂的多环嘧啶类衍生物、其制备方法及用途
WO2022171018A1 (zh) * 2021-02-09 2022-08-18 苏州泽璟生物制药股份有限公司 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
WO2022170802A1 (zh) * 2021-02-09 2022-08-18 苏州阿尔脉生物科技有限公司 一种作为sos1抑制剂的嘧啶并吡啶酮类衍生物、其制备方法及用途
CN116669738A (zh) * 2021-02-09 2023-08-29 苏州阿尔脉生物科技有限公司 一种作为sos1抑制剂的嘧啶并吡啶酮类衍生物、其制备方法及用途
CN114907284A (zh) * 2021-02-10 2022-08-16 石药集团中奇制药技术(石家庄)有限公司 一种具有抗肿瘤活性的化合物及其用途
WO2022171118A1 (zh) * 2021-02-10 2022-08-18 石药集团中奇制药技术(石家庄)有限公司 一种具有抗肿瘤活性的化合物及其用途
WO2022171184A1 (zh) * 2021-02-10 2022-08-18 杭州英创医药科技有限公司 作为sos1抑制剂的杂环化合物
CN114907284B (zh) * 2021-02-10 2023-11-03 石药集团中奇制药技术(石家庄)有限公司 一种具有抗肿瘤活性的化合物及其用途
CN117295732A (zh) * 2021-02-10 2023-12-26 杭州英创医药科技有限公司 作为sos1抑制剂的杂环化合物
CN117651701A (zh) * 2021-03-02 2024-03-05 唯久生物技术(苏州)有限公司 作为sos1抑制剂的新型取代的二环氮杂杂环
WO2022184116A1 (zh) * 2021-03-05 2022-09-09 江苏先声药业有限公司 新型sos1抑制剂及其制备方法和应用
CN115028644A (zh) * 2021-03-08 2022-09-09 首药控股(北京)股份有限公司 Sos1抑制剂杂环化合物
WO2022188819A1 (zh) * 2021-03-09 2022-09-15 苏州泽璟生物制药股份有限公司 Sos1蛋白水解调节剂及其制备方法和应用
CN115043817A (zh) * 2021-03-09 2022-09-13 苏州泽璟生物制药股份有限公司 Sos1蛋白水解调节剂及其制备方法和应用
WO2022199635A1 (zh) * 2021-03-25 2022-09-29 南京明德新药研发有限公司 苄氨基喹唑啉类衍生物
CN116917286A (zh) * 2021-03-26 2023-10-20 南京明德新药研发有限公司 6-氨基甲酸酯取代的杂芳环衍生物
WO2022199670A1 (zh) * 2021-03-26 2022-09-29 南京明德新药研发有限公司 6-氨基甲酸酯取代的杂芳环衍生物
CN115197217A (zh) * 2021-04-14 2022-10-18 苏州信诺维医药科技股份有限公司 一种稠环化合物及其应用
CN115197218A (zh) * 2021-04-14 2022-10-18 苏州信诺维医药科技股份有限公司 一种稠环化合物及其应用
CN115215847A (zh) * 2021-04-16 2022-10-21 中国科学院上海药物研究所 一类kras-sos1抑制剂、其制备方法及其应用
CN115215847B (zh) * 2021-04-16 2025-05-13 中国科学院上海药物研究所 一类kras-sos1抑制剂、其制备方法及其应用
WO2022222875A1 (zh) * 2021-04-19 2022-10-27 昆药集团股份有限公司 一种苯并嘧啶三环衍生物及其制备方法和应用
CN115215884A (zh) * 2021-04-19 2022-10-21 昆药集团股份有限公司 苯并嘧啶三环类衍生物及其制备方法和应用
CN115232108A (zh) * 2021-04-23 2022-10-25 上海领泰生物医药科技有限公司 Sos1降解剂及其制备方法和应用
CN115232108B (zh) * 2021-04-23 2025-04-18 领泰生物医药(绍兴)有限公司 Sos1降解剂及其制备方法和应用
WO2022258057A1 (en) * 2021-06-11 2022-12-15 Jingrui Biopharma Co., Ltd. Compounds as anticancer agents
WO2022262691A1 (en) * 2021-06-17 2022-12-22 Beijing Innocare Pharma Tech Co., Ltd. Heterocyclic compounds as sos1 inhibitors
WO2022268209A1 (zh) * 2021-06-24 2022-12-29 四川汇宇制药股份有限公司 一种嘧啶并环结构衍生物及其用途
CN117580836A (zh) * 2021-06-24 2024-02-20 四川汇宇制药股份有限公司 一种嘧啶并环结构衍生物及其用途
WO2023001229A1 (zh) * 2021-07-23 2023-01-26 浙江海正药业股份有限公司 嘧啶并环类衍生物及其制备方法和用途
CN115677699A (zh) * 2021-07-23 2023-02-03 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
CN117769556A (zh) * 2021-07-23 2024-03-26 浙江海正药业股份有限公司 嘧啶并环类衍生物及其制备方法和用途
CN115677824B (zh) * 2021-07-26 2026-02-03 中国科学院上海药物研究所 可诱导sos1蛋白质降解的化合物、制备方法和用途
CN115677824A (zh) * 2021-07-26 2023-02-03 中国科学院上海药物研究所 可诱导sos1蛋白质降解的化合物、制备方法和用途
CN115677601A (zh) * 2021-07-29 2023-02-03 石药集团中奇制药技术(石家庄)有限公司 一种具有抗肿瘤活性的化合物及其用途
CN115677601B (zh) * 2021-07-29 2025-06-03 石药集团中奇制药技术(石家庄)有限公司 一种具有抗肿瘤活性的化合物及其用途
CN117940411A (zh) * 2021-08-30 2024-04-26 浙江海正药业股份有限公司 喹唑啉类衍生物、或其制备方法和用途
WO2023030216A1 (zh) * 2021-08-30 2023-03-09 浙江海正药业股份有限公司 喹唑啉类衍生物、或其制备方法和用途
CN115417868A (zh) * 2021-09-13 2022-12-02 石药集团中奇制药技术(石家庄)有限公司 一种具有抗肿瘤活性的杂环化合物及其用途
CN115417868B (zh) * 2021-09-13 2024-04-02 石药集团中奇制药技术(石家庄)有限公司 一种具有抗肿瘤活性的杂环化合物及其用途
CN115246841B (zh) * 2021-09-14 2024-02-09 北京福元医药股份有限公司 苄氨基取代的嘧啶并吡喃酮衍生物及其组合物、制剂和用途
CN115246841A (zh) * 2021-09-14 2022-10-28 北京福元医药股份有限公司 苄氨基取代的嘧啶并吡喃酮衍生物及其组合物、制剂和用途
CN115536660A (zh) * 2021-11-04 2022-12-30 北京福元医药股份有限公司 苄氨基取代的杂多环化合物及其组合物、制剂和用途
CN115536660B (zh) * 2021-11-04 2025-09-02 北京福元医药股份有限公司 苄氨基取代的杂多环化合物及其组合物、制剂和用途
CN116143708A (zh) * 2021-11-21 2023-05-23 四川汇宇制药股份有限公司 一种多取代苯并氮杂芳基衍生物及其用途
WO2023109929A1 (zh) 2021-12-17 2023-06-22 石药集团中奇制药技术(石家庄)有限公司 一种具有抗肿瘤活性的杂环化合物及其用途
WO2023138526A1 (zh) * 2022-01-21 2023-07-27 南京明德新药研发有限公司 含烯丙基的甲基吡啶并嘧啶化合物的晶型
WO2023143147A1 (zh) * 2022-01-28 2023-08-03 上海优理惠生医药有限公司 一种哒嗪并吡啶酮类化合物、其药物组合物及应用
CN116768858A (zh) * 2022-03-15 2023-09-19 杭州中美华东制药有限公司 具有kras-sos1抑制或降解活性的嵌合化合物及其用途
CN117024404A (zh) * 2022-05-10 2023-11-10 四川汇宇制药股份有限公司 苯并吡啶衍生物及其用途
WO2023241414A1 (zh) * 2022-06-13 2023-12-21 上海优理惠生医药有限公司 一种哒嗪类化合物、其药物组合物及应用
WO2024008185A1 (zh) * 2022-07-07 2024-01-11 武汉人福创新药物研发中心有限公司 包含sos1抑制剂的药物组合物
CN119894894A (zh) * 2022-09-23 2025-04-25 无锡瓴方生物医药科技有限公司 喹唑啉类化合物的晶型及其制备方法
WO2024061353A1 (zh) * 2022-09-23 2024-03-28 南京明德新药研发有限公司 喹唑啉类化合物的晶型及其制备方法
CN119894894B (zh) * 2022-09-23 2025-12-05 无锡瓴方生物医药科技有限公司 喹唑啉类化合物的晶型及其制备方法
CN119907792A (zh) * 2022-10-21 2025-04-29 领泰生物医药(绍兴)有限公司 苄基或噻吩亚甲基取代的氨基喹唑啉衍生物及其作为sos1降解剂的用途
CN119907792B (zh) * 2022-10-21 2025-12-09 领泰生物医药(绍兴)有限公司 苄基或噻吩亚甲基取代的氨基喹唑啉衍生物及其作为sos1降解剂的用途
CN116444447A (zh) * 2023-06-19 2023-07-18 中国药科大学 一种sos1和hdac双靶点喹唑啉羟肟酸化合物及其制法和应用
CN116444447B (zh) * 2023-06-19 2023-09-22 中国药科大学 一种sos1和hdac双靶点喹唑啉羟肟酸化合物及其制法和应用

Also Published As

Publication number Publication date
EP3558979B1 (en) 2021-02-17
US10898487B2 (en) 2021-01-26
EP3878850A1 (en) 2021-09-15
JP7219218B2 (ja) 2023-02-07
WO2018115380A1 (en) 2018-06-28
US20190358230A1 (en) 2019-11-28
EP3558979A1 (en) 2019-10-30
JP2020504742A (ja) 2020-02-13
US12053473B2 (en) 2024-08-06
US20210177851A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
JP7219218B2 (ja) 新規のベンジルアミノ置換キナゾリンおよびsos1阻害剤としての誘導体
JP7808058B2 (ja) がんを治療するための縮合環化2-アミノ-3-シアノチオフェン及び誘導体
JP7189956B2 (ja) Sos1阻害剤としての新規なベンジルアミノ置換ピリドピリミジノンおよび誘導体
JP2024543983A (ja) がんの処置のための縮環2-アミノ-3-シアノチオフェン及び誘導体
AU2022402390A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099608A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099623A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
KR20220024191A (ko) 항암제 조합 요법
HK40097417A (en) Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
HK40039222B (en) Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
HK40039222A (en) Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
BR112020010123B1 (pt) Piridopirimidinonas substituídas por benzilamino, derivados como inibidores de sos1, composições e preparações farmacêuticas, bem como seus usos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination